<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05046665</url>
  </required_header>
  <id_info>
    <org_study_id>ZiPUP</org_study_id>
    <nct_id>NCT05046665</nct_id>
    <nct_alias>NCT05018442</nct_alias>
  </id_info>
  <brief_title>A Single-centre, Open-label, Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP Study)</brief_title>
  <acronym>ZiPUP</acronym>
  <official_title>A Single-centre, Open-label, Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South Metropolitan Health Service</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Telix International Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>South Metropolitan Health Service</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine if it is practical to use 89Zr-TLX250 PET/CT in the&#xD;
      staging and detection of localized and metastatic urothelial carcinoma or bladder cancer.&#xD;
&#xD;
      The primary objective is to evaluate the feasibility of using 89Zr-TLX250 PET/CTas a new&#xD;
      diagnostic and staging modality to detect urothelial carcinoma or bladder cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a non-randomised, non-blinded, single centre, phase 1 feasibility study&#xD;
      comparing 89Zr-girentuximab PET with FDG PET in patients with urothelial carcinoma or bladder&#xD;
      cancer. This study would include 2 cohorts of adult patients; those with known metastatic&#xD;
      urothelial carcinoma and bladder cancer and those undergoing primary staging for recently&#xD;
      diagnosed urothelial carcinoma or bladder cancer.&#xD;
&#xD;
      This study is open-label, single centre and eligible patients will receive a single&#xD;
      administration of study drug prior to imaging on day 5 (+/- 2 days). PET scans will be&#xD;
      independently interpreted by nuclear medicine physicians blinded to the FDG PET findings. For&#xD;
      patients proceeding to radical cystectomy, subsequent histological confirmation of areas of&#xD;
      increased uptake will be retrospectively correlated with both PET scans.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 14, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Group Assignment</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the sensitivity and specificity of 89Zr-girentuximab PET with FDG PET</measure>
    <time_frame>Day 1 - Day 90</time_frame>
    <description>Sensitivity and specificity will be established following histological confirmation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the correlation between 89Zr-girentuximab SUV's and degree of urinary carbonic anhydrase IX excretion (cytology and CA-IX via PCR).</measure>
    <time_frame>Day 1</time_frame>
    <description>89Zr-girentuximab SUV's will be correlated with urinary CA-IX expression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate safety parameters related to 89Zr-girentuximab administration</measure>
    <time_frame>Day 1 to Day 90</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by NCI-CTCAE v 5.0 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the correlation between tumour volume using MIM quantitative software and histopathological findings</measure>
    <time_frame>Day 1 - Day 90</time_frame>
    <description>Tumour burden as defined by volumetric software will be correlated with histopathological results</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Staging cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Eligible participants recruited to the staging cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metastatic cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Eligible participants recruited from the metastatic cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>89Zr-Girentuximab</intervention_name>
    <description>Administration of 89Zr-girentuximab as per protocol.</description>
    <arm_group_label>Metastatic cohort</arm_group_label>
    <arm_group_label>Staging cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 18 or older with bladder cancer or urothelial carcinoma who are able to&#xD;
             provide informed consent&#xD;
&#xD;
          2. Negative serum pregnancy test in female patients of childbearing potential at&#xD;
             screening. Confirmation of negative pregnancy test result from urine within 24 hours&#xD;
             prior to receiving investigational product.&#xD;
&#xD;
          3. Consent to practise double-barrier contraception until a minimum of 42 days after&#xD;
             89Zr-TLX250 administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active malignancy other than urothelial carcinoma or bladder cancer&#xD;
&#xD;
          2. Administration of a radioisotope within 10 physical half-lives prior to study&#xD;
             enrolment.&#xD;
&#xD;
          3. Administration of chemotherapy, radiotherapy, or immunotherapy within 4 weeks prior to&#xD;
             planned administration of 89Zr-TLX250 or continuing adverse effects from such therapy&#xD;
&#xD;
          4. Planned antineoplastic therapies for the period between administration of 89Zr-TLX250&#xD;
             and imaging&#xD;
&#xD;
          5. Serious non-malignant disease that may interfere with the objectives of the study&#xD;
&#xD;
          6. Renal insufficiency with glomerular filtration rate â‰¤45 mL/min/1.73m2&#xD;
&#xD;
          7. Pregnancy or lactation&#xD;
&#xD;
          8. Exposure to murine or chimeric antibodies within the last 5 years&#xD;
&#xD;
          9. Known hypersensitivity or human anti-chimeric antibodies against girentuximab&#xD;
&#xD;
         10. Exposure to any experimental diagnostic or therapeutic drug 30 days prior to the date&#xD;
             of planned administration of 89Zr-TLX250&#xD;
&#xD;
         11. Contraindications to FDG PET/CT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dickon Hayne</last_name>
      <phone>61 8 6152 2222</phone>
      <email>dickon.hayne@uwa.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Cynthia Hawks</last_name>
      <phone>61 8 6152 6916</phone>
      <email>Cynthia.Hawks@health.wa.gov.au</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 8, 2021</study_first_submitted>
  <study_first_submitted_qc>September 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glandular and Epithelial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

